Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.
OBJECTIVE
The premise for phase I trials for cytostatic agents is different from that of cytotoxic agents. For cytostatic agents, toxicity and efficacy do not necessarily increase monotonically with increasing dose levels, but likely plateau after they reach maximal toxicity or efficacy. Here, we propose a phase I-II trial design to assess both toxicity and efficacy to find the best dose as well as a good dose.


METHODS
We propose a 2-step dose-finding trial for assessing both toxicity and efficacy for a targeted agent. The 1st step uses a traditional phase I trial design. This step only assesses toxicity and finds the maximal tolerated dose (MTD). For the 2nd step, we propose a modified phase II selection design for 2 or 3 dose levels at and below the MTD to determine efficacy and evaluate each dose level by both efficacy and toxicity.


CONCLUSIONS
Simulation studies are done on several combinations of toxicity and efficacy scenarios to assess the operating statistics of our proposed trial design. We then compare our results with a traditional phase I trial followed by a single-arm phase II trial using the same total sample size. The proposed design does better in most cases than a traditional design using the same overall sample size. This design allows assessing a few dose levels more closely for both efficacy and toxicity and provides greater certainty of having correctly determined the best dose level before launching into a large efficacy trial.
Cancer Research and Biostatistics, Seattle, Washington 98101-1468, USA. antjeh@crab.org
Antje
A
Hoering
Mike
M
LeBlanc
John
J
Crowley
D000818:Animals; D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D054697:Cytostatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D020714:Maximum Tolerated Dose; D008962:Models, Theoretical; D058990:Molecular Targeted Therapy; D012107:Research Design
D054697:Cytostatic Agents